Anti-Congestive Raw Powder Milrinone Pharmaceutical Powder Milrinone Milrinone

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Milrinone
• Product Name: Milrinone
• Name: Milrinone Powder
• Appearance: off-White to White Powder
• Color: off-White to White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anti-Congestive
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 78415-72-2
• Mf: C12h9n3o
• MW: 211.224
• Boiling Point: 448.7 °c at 760 Mmhg
• Density: 1.28
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Anti-Congestive Raw Powder Milrinone Pharmaceutical Powder Milrinone Milrinone

Product Description

Product Details

Product name	Milrinone
Appearance	Off-white to white powder
CAS NO.	78415-72-2
MF	C12H9N3O
MW	211.224

Milrinone is a PDE3 (phosphodiesterase 3) inhibitor that exhibits vasodilator and positive inotropic effects. Milrinone's positive inotropic activity can be inhibited by carbachol (sc-202092). Research indicates that Milrinone can increase platelets and enhance cAMP levels. Milrinone is an inhibitor of PDE3A and PDE3B.
Milrinone, commonly known and marketed as the drug Primacor, is a medication used in patients suffering from heart failure. Milrinone is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility. Milrinone also works to vasodilate vessels which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. Milrinone has been used in those suffering from heart failure for many years.

Application&Function

Milrinone, is a medication used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, recent studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. 

Specification